The "rights" of precision drug development for Alzheimer's disease.
TLDR
Attention to disciplined drug development will increase the likelihood of success, decrease the risks associated with AD drug development, enhance the ability to attract investment, and make it more likely that new therapies will become available to those with or vulnerable to the emergence of AD.Abstract:
There is a high rate of failure in Alzheimer’s disease (AD) drug development with 99% of trials showing no drug-placebo difference. This low rate of success delays new treatments for patients and discourages investment in AD drug development. Studies across drug development programs in multiple disorders have identified important strategies for decreasing the risk and increasing the likelihood of success in drug development programs. These experiences provide guidance for the optimization of AD drug development. The “rights” of AD drug development include the right target, right drug, right biomarker, right participant, and right trial. The right target identifies the appropriate biologic process for an AD therapeutic intervention. The right drug must have well-understood pharmacokinetic and pharmacodynamic features, ability to penetrate the blood-brain barrier, efficacy demonstrated in animals, maximum tolerated dose established in phase I, and acceptable toxicity. The right biomarkers include participant selection biomarkers, target engagement biomarkers, biomarkers supportive of disease modification, and biomarkers for side effect monitoring. The right participant hinges on the identification of the phase of AD (preclinical, prodromal, dementia). Severity of disease and drug mechanism both have a role in defining the right participant. The right trial is a well-conducted trial with appropriate clinical and biomarker outcomes collected over an appropriate period of time, powered to detect a clinically meaningful drug-placebo difference, and anticipating variability introduced by globalization. We lack understanding of some critical aspects of disease biology and drug action that may affect the success of development programs even when the “rights” are adhered to. Attention to disciplined drug development will increase the likelihood of success, decrease the risks associated with AD drug development, enhance the ability to attract investment, and make it more likely that new therapies will become available to those with or vulnerable to the emergence of AD.read more
Citations
More filters
Journal ArticleDOI
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
TL;DR: For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but recent results have shown that they could become a reality as discussed by the authors , and the question emerges of when and how we can bring these biomarkers to clinical practice.
Journal ArticleDOI
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.
Charlotte E. Teunissen,Inge M.W. Verberk,Elisabeth H. Thijssen,Lisa Vermunt,Oskar Hansson,Henrik Zetterberg,Wiesje M. van der Flier,Michelle M. Mielke,Marta Del Campo,Marta Del Campo +9 more
TL;DR: In this article, blood-based biomarkers of neurodegeneration, such as neurofilament light chain and glial fibrillary acidic protein, appear to provide information on disease progression and potential for monitoring treatment effects.
Journal ArticleDOI
Gut Microbiota and Dysbiosis in Alzheimer's Disease: Implications for Pathogenesis and Treatment.
TL;DR: An overview of gut microbiota and their dysregulation in the pathogenesis of Alzheimer’s disease is provided and novel insights into the modification of Gut microbiota composition as a preventive or therapeutic approach for AD are highlighted.
Journal ArticleDOI
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
Journal ArticleDOI
Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study.
Adrian L. Oblak,Peter Bor-Chian Lin,Kevin P. Kotredes,Ravi S. Pandey,Dylan Garceau,Harriet M. Williams,Asli Uyar,Rita O'Rourke,Sarah O'Rourke,Cynthia M. Ingraham,Daria Bednarczyk,Melisa Belanger,Zackary A. Cope,Gabriela J. Little,Sean-Paul G. Williams,Carl Ash,Adam Bleckert,Tim Ragan,Benjamin A. Logsdon,Lara M. Mangravite,Stacey J. Sukoff Rizzo,Paul R. Territo,Gregory W. Carter,Gareth R. Howell,Michael Sasner,Bruce T. Lamb +25 more
TL;DR: In this paper, a detailed characterization of the 5XFAD mouse was conducted, including transcriptomics, electroencephalogram, in vivo imaging, biochemical characterization, and behavioral assessments.
References
More filters
Journal ArticleDOI
The Clinical Dementia Rating (CDR): Current version and scoring rules
Journal ArticleDOI
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack,David A. Bennett,Kaj Blennow,Maria C. Carrillo,Billy Dunn,Samantha Budd Haeberlein,David M. Holtzman,William J. Jagust,Frank Jessen,Jason Karlawish,Enchi Liu,José Luis Molinuevo,Thomas J. Montine,Creighton H. Phelps,Katherine P. Rankin,Christopher C. Rowe,Philip Scheltens,Eric Siemers,Heather M. Snyder,Reisa A. Sperling,Cerise L Elliott,Eliezer Masliah,Laurie M. Ryan,Nina Silverberg +23 more
TL;DR: This research framework seeks to create a common language with which investigators can generate and test hypotheses about the interactions among different pathologic processes (denoted by biomarkers) and cognitive symptoms and envision that defining AD as a biological construct will enable a more accurate characterization and understanding of the sequence of events that lead to cognitive impairment that is associated with AD.
Journal ArticleDOI
2016 Alzheimer's disease facts and figures
Journal ArticleDOI
A new rating scale for Alzheimer's disease.
TL;DR: A new rating instrument, the Alzheimer's Disease Assessment Scale, was designed specifically to evaluate the severity of cognitive and noncognitive behavioral dysfunctions characteristic of persons with Alzheimer's disease.
Journal ArticleDOI
Forecasting the global burden of Alzheimer’s disease
TL;DR: The goal was to forecast the global burden of Alzheimer's disease and evaluate the potential impact of interventions that delay disease onset or progression.
Related Papers (5)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack,David A. Bennett,Kaj Blennow,Maria C. Carrillo,Billy Dunn,Samantha Budd Haeberlein,David M. Holtzman,William J. Jagust,Frank Jessen,Jason Karlawish,Enchi Liu,José Luis Molinuevo,Thomas J. Montine,Creighton H. Phelps,Katherine P. Rankin,Christopher C. Rowe,Philip Scheltens,Eric Siemers,Heather M. Snyder,Reisa A. Sperling,Cerise L Elliott,Eliezer Masliah,Laurie M. Ryan,Nina Silverberg +23 more
Alzheimer's disease drug-development pipeline: few candidates, frequent failures
The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann,Guy M. McKhann,David S. Knopman,Howard Chertkow,Bradley T. Hyman,Clifford R. Jack,Claudia H. Kawas,William E. Klunk,Walter J. Koroshetz,Jennifer J. Manly,Richard Mayeux,Richard C. Mohs,John C. Morris,Martin N. Rossor,Philip Scheltens,Maria C. Carrillo,Bill Thies,Sandra Weintraub,Creighton H. Phelps +18 more
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Jeff Sevigny,Ping Chiao,Thierry Bussiere,Paul H. Weinreb,Leslie Williams,Marcel Maier,Robert Dunstan,Stephen Salloway,Tianle Chen,Yan Ling,John O'Gorman,Fang Qian,Mahin Arastu,Mingwei Li,Sowmya Chollate,Melanie S. Brennan,Omar Quintero-Monzon,Robert H. Scannevin,H. Moore Arnold,Thomas Engber,Kenneth J. Rhodes,James Ferrero,Yaming Hang,Alvydas Mikulskis,Jan Grimm,Christoph Hock,Roger M. Nitsch,Alfred Sandrock +27 more
Neuroinflammation in Alzheimer's disease
Michael T. Heneka,Monica J. Carson,Joseph El Khoury,Gary E. Landreth,Frederic Brosseron,Douglas L. Feinstein,Andreas H. Jacobs,Tony Wyss-Coray,Tony Wyss-Coray,Javier Vitorica,Richard M. Ransohoff,Karl Herrup,Sally A. Frautschy,Bente Finsen,Guy C. Brown,Alexei Verkhratsky,Alexei Verkhratsky,Alexei Verkhratsky,Koji Yamanaka,Jari Koistinaho,Eicke Latz,Eicke Latz,Annett Halle,Gabor C. Petzold,Terrence Town,Dave Morgan,Mari L. Shinohara,V. Hugh Perry,Clive Holmes,Clive Holmes,Nicolas G. Bazan,David J. Brooks,Stéphane Hunot,Bertrand Joseph,Nikolaus Deigendesch,Olga Garaschuk,Erik Boddeke,Charles A. Dinarello,John C.S. Breitner,Greg M. Cole,Douglas T. Golenbock,Markus P. Kummer +41 more